ALPHAEON Corporation today announced it has entered into a definitive agreement with PhysIOL SA of Belgium, to jointly develop and commercialize an exclusive ALPHAEON-branded Trifocal lens technology. Specific terms of the agreement were not disclosed.
PhysIOL's dynamic R&D has developed a range of innovative products, designed in partnership with ophthalmic surgeons as well as specialized research centers and universities. This unique partnership enables ALPHAEON to bring PhysIOL Trifocal lens technology to the US for the first time, providing significant benefits to patients and physicians alike.
"We are very pleased to collaborate with PhysIOL, an innovative leader in advanced Trifocal intraocular lens technology (IOL)," said Robert E. Grant, CEO of ALPHAEON. "With this new agreement, we will seek to advance the premium category for patients looking for excellent visual acuity outcomes across their range of vision, at near, mid and distance. PhysIOL has already established itself as the leading innovator in Trifocal IOL technology across Europe and Asia. Together, we'll continue to develop the global self-pay market within ophthalmology, with particular focus in the U.S."
"ALPHAEON's development and regulatory capabilities combined with our expertise in design and manufacturing of Trifocal IOL technologies make this an ideal partnership," said Marc Nolet, CEO, PhysIOL. "Additionally, we're excited to leverage ALPHAEON's market access through its highly innovative ShoutMD proprietary social commerce platform."
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy